FDA EUA If the FDA thought that AcuVid was a deadend they would not have requested this additional information. The fact that Rob and his team could promptly and successfully meet the expectations bodes extremely well for FDA EUA approval.
The THRM sp should now easily move past Morningstar's Fair Value sp of $.42. With testing ramping up for schools, businesses etc and (in many situations) even for those who have been vaccinated AcuVid could be a game changer.
This is a great article on the situation in Australia and presents the significant upside to serial testing with rapid antigen tests. That AcuVid could be one of the cheapest, most accurate and easily used tests on the market suggests significant upside.
https://www.smh.com.au/national/what-s-rapid-antigen-testing-and-is-it-about-to-become-part-of-daily-life-20210831-p58ndj.html
GLTE!!!